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Summary
Poor sleep is an increasingly recognised problem with chronic pain and further increases the effect on daily function.
To identify the relationship between chronic pain, opioid analgesia and sleep quality, this study investigated activity
and sleep patterns in patients taking opioid and non-opioid analgesia for chronic back pain. Thirty-one participants
(10 healthy controls, 21 patients with chronic pain: 6 on non-opioid medication; 15 on opioid medication) were
assessed using actigraphy, polysomnography and questionnaires. Patients with chronic pain subjectively reported sig-
niﬁcant sleep and wake disturbances as shown by decreased overall sleep quality (Pittsburgh Sleep Quality Index,
p < 0.001), increased symptoms of insomnia (Insomnia Severity Index, p < 0.001) and increased fatigue (Fatigue
Severity Scale, p = 0.002). They also spent increased time in bed (p = 0.016), took longer to get to sleep (p = 0.005)
and had high interindividual variability in other measures of activity but no overall irregular rest-activity pattern.
Patients on high doses of opioids (> 100 mg morphine-equivalent/day) demonstrated distinctly abnormal brain activ-
ity during sleep suggesting that polysomnography is necessary to detect sleep disturbance in this population in the
absence of irregular rest-activity behaviour. Night-time sleep disturbance is common in individuals suffering from
chronic pain and may be further exacerbated by opioid treatment. Considerations must be made regarding the
appropriate use of combined actigraphy and miniaturised polysomnography for future population-based studies.
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Introduction
Sleep disruption has been associated with a wide range
of health problems including reduced daily function
[1], increased pain [2], psychiatric disorders [3] and
type-2 diabetes [4]. It is also a common problem in
patients with chronic pain [5, 6] with one study
reporting 89% of 287 chronic pain patients experienc-
ing disrupted sleep [2]. The prevalence of chronic pain
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has been estimated to be 19% in European adults and
up to 41% in low-income countries [7, 8]. Opioid
medication, estimated to be prescribed to 28% of
patients with chronic pain in Europe [7], has been
shown to decrease deep sleep (stages 3 and 4) and
increase stage 2 sleep on acute administration in
healthy adults [9–11], and may cause instability in
deep sleep, increased waking and decreased rapid eye
movements (REM) with chronic use in addicts [12].
Additionally, opioid-induced respiratory depression
and sleep-disordered breathing may exacerbate this
sleep disruption. One study found 85% of patients tak-
ing opioid medication (median morphine-equivalent
dose: 180 mg.day 1 [range: 7.5–935 mg]) suffer from
some form of sleep apnoea [13], and increases in cen-
tral apnoea and decreased arterial oxygen saturation
have been demonstrated in patients taking opioid
medication [14–16]. Together, the evidence highlights
a considerable problem with sleep disruption in
chronic pain, which may be particularly severe in
patients taking opioid medication.
Sleep can be assessed both subjectively, using sleep
diaries and questionnaires, and objectively, using
polysomnography. While subjective questionnaires give
an insight into patients’ experiences of pain and sleep
disturbance, objective polysomnography allows a more
direct assessment of physiological differences. Actigra-
phy is a useful additional measure to monitor rest/ac-
tivity behaviour to detect abnormal circadian and
ultradian patterns. Discrepancies between objective and
subjective measurements of sleep may be common [17,
18]. For example, insomnia sufferers have been found
to report shorter sleep duration than healthy controls
with a similar objective sleep length [18], suggesting
an impact of sleep perception on overall quality.
Therefore, to adequately assess the impact of sleep dis-
ruption on an individual, both objective and subjective
measurements are necessary. Actigraphy uses long-
term monitoring of the level of activity from arm
movement as a proxy for wake rest. Sleep-wake timing
and movement-related sleep parameters are then
inferred from this data. As an inexpensive and mini-
mally disruptive device, actigraphy has the potential to
be used for large population-based studies, enabling
researchers to gather rest-activity data over lengthy
periods of time but not cortical sleep or breathing
data. Polysomnography, with overnight electroen-
cephalography derived from electrical brain activity
and additional physiological measurements, allows
determination of sleep stages and structure as corre-
lates of sleep in addition to measurements of respira-
tory events during sleep. While this gives very detailed
information about sleep, it is time and resource
intense.
Little research has directly addressed the question
of how opioid medication may affect subjective and
objective sleep in chronic pain patients. Actigraphy
studies have shown that people with chronic pain
spend more time in bed, have a lower sleep efﬁciency
than healthy individuals and lower number of move-
ment-related awakenings after sleep onset [19, 20].
One study showed that individuals with prescription
opioid dependence had signiﬁcantly disturbed sleep on
actigraphy in addition to subjective poor sleep quality
identiﬁed by the Pittsburgh Sleep Quality Index [21].
Polysomnography studies have identiﬁed sleep-disor-
dered breathing in patients on chronic opioid therapy
[16, 22].
This study included an evaluation of the feasibility
of actigraphy and polysomnography as techniques to
assess rest-activity timing and physiological sleep, in a
population of patients with chronic pain. From this,
the study also aimed to allow the generation of future
hypotheses regarding the effects of opioid medication
on sleep which could be formally tested in population-
based studies.
Methods
Ethical approval was obtained from the Oxford NHS
Research Ethics Committee and all participants pro-
vided written informed consent. The study included 31
participants (10 healthy controls, 21 patients with
chronic pain: 6 on non-opioid medication; 15 on opi-
oid medication). The sample size was chosen to pro-
vide preliminary data for a larger subsequent study
and was estimated to be sufﬁcient to provide an
understanding of any issues that running a larger
study may entail. Participants in both patient groups
were between the ages of 18–65 and taking opioid or
non-opioid medication for chronic back pain. The
duration of opioid medication was 1–35 years (mean
(SD) 7.5 (8.6) years). Pain medications taken by
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patients in the non-opioid group included paracetamol,
ibuprofen, amitriptyline and diclofenac. Exclusion cri-
teria included any signiﬁcant cardiac, respiratory, neu-
rological or metabolic disease; evidence or history of
substance misuse; travel across more than two time
zones in the previous month or travel across one time
zone in the previous week; and shift work. Inclusion
criteria for healthy controls included no signiﬁcant co-
morbidity and not taking any opioid, antidepressant or
sleep medication.
All participants completed six questionnaires in
order to assess their subjective impression of their
sleep and pain: the Pittsburgh Sleep Quality Index
(PSQI, a composite scale with a range of 0–21, where
a higher score indicates a worse sleep quality) [23];
Insomnia Severity Index (ISI, a subjective assessment
of sleep with a score range of 0–28. A higher score
indicates increasing trouble with sleep) [24]; Pain Vigi-
lance and Awareness Questionnaire (PVAQ, a score of
pain-related experiences with a score range of 0–80
with a higher score indicating increased pain vigilance
and awareness) [25]; Centre for Epidemiological Stud-
ies Depression Scale (C-ESD, a score with a range of
0–60, with higher scores indicating increasing psycho-
logical distress) [26]; the Epworth Sleepiness Scale
(ESS, an evaluation of daytime sleepiness with a score
range of 0–24, with a higher score indicating increased
daytime sleepiness) [27]; and the Fatigue Severity Scale
(FSS, a score to assess the impact of fatigue on daily
living with a range of 9–63 with a higher score indicat-
ing a greater impact of fatigue on aspects of daily life.)
[28]. Full questionnaire details and references are
available in the Appendix. All participants wore an
actiwatch (Actiwatch-L, CamNTech Ltd., Cambridge,
UK) for 14 continuous days and kept a sleep and
activity diary, documenting bed-time, get-up time,
naps, prolonged periods of rest (e.g. watching televi-
sion) and any times the actiwatch was removed (e.g.
for swimming), during this period. Actigraphy data
were analysed with ‘Actiwatch Activity and Sleep Anal-
ysis’ software (CamNtech Motionware version 1.1.3;
Cambridge Neurotechnology, Cambridge, UK). Data
from the sleep diary were used to annotate the actigra-
phy data and to edit accordingly. Actigraphically-
derived sleep parameters such as sleep timing, sleep
efﬁciency and sleep latency, fragmentation index,
interday stability (consistency of movement patterns
over many days) and intraday variability (structural
similarity of movements within 24 h) were calculated
using the automated algorithms within the software. A
subset of 12 participants underwent two consecutive
nights of domiciliary polysomnography recording
(SomnoScreen+PSG, SOMNOmedics GmbH, Rander-
sacker, Germany). This recorded electrical activity in
the brain (electroencephalography, EEG), muscle activ-
ity (electromyography, EMG), and eye movements
(electrooculography, EOG), in addition to physiological
measurements of heart rate, oxygen saturation of arte-
rial blood, respiratory effort and ﬂow recordings. For
the EEG, a standard montage of ﬁve channels (Fz, Cz,
C3, C4, Oz) referenced to the mastoids was used, sam-
pled at 128 Hz and digitally ﬁltered using ﬁnite
impulse response (FIR) band pass ﬁltering between
0.2 Hz and 35 Hz with the Hamming window. All
data were collected in the participants’ home environ-
ment and all were encouraged to follow their usual
daily routines. The ﬁrst night acted as an adaptation
night, and data were extracted and analysed from the
second night’s recording [29]. Polysomnography data
were analysed using the DOMINO version 2.6.0 soft-
ware (SOMNOmedics GmbH) and scored according to
the American Academy of Sleep Medicine criteria with
the separation of both stage 3 and stage 4 sleep to gain
greater macrostructural detail (AASM Manual for
Scoring Sleep, 2007).
For group analysis, patients taking opioid
medication were divided into higher (~100 mg mor-
phine-equivalent.d 1) and lower dose (< 100 mg
morphine-equivalent/day) groups as it has been
demonstrated that > 100 mg may be a high-risk dose
[30]. The daily morphine-equivalent dose was calcu-
lated using a published reference [31]. All data were
analysed using SPSS (IBM Corp. Released 2012. IBM
SPSS Statistics for Macintosh, Version 21.0; Armonk,
NY: IBM Corp). Questionnaire results were analysed
with the Mann–Whitney U-test, adjusted for multiple
comparisons using a Bonferroni corrected signiﬁcance
value of a = 0.0056. Relevant actigraphic parameters
were compared with the Mann–Whitney U-test with a
signiﬁcance value of a = 0.05. Polysomnography data
were similarly analysed with the Mann–Whitney U-test
and generalised linear models for count and
1298 © 2016 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists of Great Britain and Ireland.
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proportion data. Finally, a regression analysis was car-
ried out to compare questionnaire and actigraphic
parameters with opioid dose. The primary outcome
measures (actigraphic sleep fragmentation, sleep efﬁ-
ciency and opioid dosage) for one participant was
three standard deviations above the mean and was
therefore removed from this analysis due to a statisti-
cal relationship that was unable to be conﬁrmed from
this small sample size (n = 14) [32]. Please see the
appendix for regression analysis and plots with and
without the outlier.
Results
Thirty-one participants (10 healthy controls, 21
patients with chronic pain) took part in the study.
Compliance with questionnaires, actigraphy and sleep
diaries was very good with few cases of incomplete
data due to not keeping the actiwatch on or inaccurate
diary data. Polysomnography, particularly after a trial
night, was also well-tolerated, allowing participants to
sleep in their own, natural environment. The charac-
teristics of participants in each group are shown in
Table 1.
Taking into account all participants taking opioid
medication, with the exception of an outlier (n = 13),
linear regression revealed no relationship between opi-
oid dosage and pain rating, subjective sleep quality
(PSQI), or any actigraphic measurement (adjusted R-
squared 0.14, p value 0.69). Representative actograms
and EEG hypnograms of participants from each group
are shown in Figs. 1 and 2, respectively. Several
patients experiencing chronic pain had severely frag-
mented sleep compared with healthy controls (Fig. 1).
Polysomnographic sleep assessment revealed that two
out of the four patients taking > 100 mg morphine-
equivalent.d 1 had extremely abnormal hypnograms
with deﬁcits in deep sleep, REM sleep, decreased respi-
ratory rate and a high frequency of obstructive and
central sleep apnoea compared with all other partici-
pants.
Discussion
To the authors’ knowledge, this is the ﬁrst study to
directly contrast subjective and objective sleep parame-
ters with the use of questionnaires, actigraphy and
polysomnography in patients taking opioid medication
for chronic pain, patients not taking opioid medication
for chronic pain and healthy controls. Substantial sleep
disruption was identiﬁed in patients experiencing
chronic pain, which was primarily revealed through
subjective measures, although objective actigraphy
indicated longer sleep onset latency and greater time
in bed. No differences in subjective sleep measures or
actigraphic parameters were found between patients
taking high doses of opioid medication, and patients
not taking opioid medication. However, analysis of
individual data demonstrated markedly abnormal
polysomnographic sleep architecture and increased
sleep-disordered breathing in two out of four opioid
users. These ﬁndings suggest that chronic pain can be
associated with signiﬁcant disruption in brain activity
during sleep. Furthermore, this disruption is not
improved, and may even be exacerbated, in patients
taking opioid medication.
Subjective parameters revealed that patients experi-
encing chronic pain had decreased sleep quality
(PSQI), increased symptoms of insomnia (ISI),
increased fatigue (FSS) and a trend towards increased
daytime sleepiness (ESS). In particular, daytime sleepi-
ness was increased in the high-dose opioid group.
Although this increase was not signiﬁcant, the median
score (15) was greater than the upper threshold (10)
for ‘normal’ ESS values [33]. This indicates that the
longer time to sleep onset and longer time in bed as
revealed by actigraphic measures may be due to
increased sedation that may not have been restful and
induced daytime sleepiness. No differences were found
in the fragmentation index or sleep efﬁciency, two pri-
mary measures of sleep disruption, which might be
explained by high variability within groups and a small
sample size, or masking due to medication side-effects.
Previous research using actigraphy in patients with
chronic pain has been largely inconclusive. A study in
older persons with chronic pain also identiﬁed worse
PSQI sleep quality scores but no difference in daytime
sleepiness using the Epworth Rating Scale [19]. Acti-
graphically derived time in bed was longer but no dif-
ferences were found for total sleep time, sleep
efﬁciency or sleep onset latency. Patients with chronic
lower back pain were found to have signiﬁcantly worse
PSQI sleep quality scores and lower actigraphic sleep
efﬁciency but no differences in actigraphic sleep onset
© 2016 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists of Great Britain and Ireland. 1299
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latency or total sleep time [20]. Inconsistencies likely
arise across the literature due to variable population
groups with heterogeneous primary pain symptoms,
medication use, age and methodological differences
including recording length, sampling interval and scor-
ing algorithm used. The longer total sleep time of
patients in our study may be explained by the sedative
effects of medication, and by the rather heterogeneous
control group.
Poor sleep quality (PSQI > 5) was identiﬁed in 93%
of individuals taking opioid medication compared with
20% of the control group and the Epworth sleepiness
scale revealed that ﬁve of six participants rated as ‘exces-
sively sleepy during the day’ were taking opioid medica-
tion. Overall, no differences were found in terms of any
subjective or objective sleep parameters for patients tak-
ing high doses of opioids compared with those not tak-
ing opioids. Further, no association was found with any
sleep PSG or actigraphic parameters and increasing
daily opioid dose. This ﬁnding is consistent with previ-
ous research revealing no effect of opioid medication on
polysomnographically determined total sleep time, sleep
Table 1 Sleep and rest-activity characteristics of study participants. Values are mean (SD).
Participant group (medians [IQR])
p value,
patients
vs.
controls
p value,
high-dose
vs. non-
opioid
High-dose
opioid
medication
n = 4
Low-dose
opioid
medication
n = 11
Non-opioid
medication
n = 6
Healthy
controls
n = 10
Group characteristics
Age; years 42 (28) 44 (22) 44 (28) 44 (27) – –
Morphine-equivalent.d1; mg 116.5 (89.5) 10 (68.9) 0 0 – –
Number of men n = 2 n = 4 n = 3 n = 6
Subjective sleep, pain and mood
Sleep quality (PSQI) 10.5 (3.3) 15.0 (7.0) 11.0 (8.0) 3.0 (2.5) <0.001 0.915
Insomnia symptoms (ISI) 11 (2) 18 (10) 16 (15) 2 (3) <0.001 0.915
Daytime sleepiness (ESS) 15.0 (6.6) 7 (11.5) 6.0 (11.1) 4.5 (7.8) 0.056 0.114
Fatigue (FSS) 43.5 (21.5) 36.0 (13.5) 55.0 (25.3) 20.5 (10.3) 0.002 0.669
Pain rating (PVAQ) 56.0 (28.8) 49.0 (20.0) 51.0 (32.0) 32.5 (16.3) <0.001 0.762
Depressive symptoms
(CESD)
22.0 (17.0) 12.0 (23.0) 12.0 (15.0) 5.5 (6.3) 0.012 0.392
Actigraphic sleep parameters
Time in bed; h 10.0 (2.1) 8.7 (1.6) 9.4 (2.0) 8.0 (1.4) 0.016 0.257
Total sleep time; h 7.9 (2.5) 7.3 (1.0) 6.9 (1.9) 6.4 (1.0) 0.026 0.610
Sleep efficiency; % 81.9 (24.7) 87.6 (3.3) 82.1 (10.2) 83.8 (4.3) 0.808 1
Sleep latency; min 30.0 (44.2) 24.9 (20.5) 23.2 (21.9) 11.0 (8.6) 0.005 0.476
Fragmentation index 37.1 (71.0) 29.6 (11.0) 36.1 (16.2) 34.3 (13.0) 0.725 0.914
Interdaily stability 0.6 (0.2) 0.5 (0.2) 0.5 (0.2) 0.3 (0.2) 0.059 0.521
Intradaily variability 0.8 (0.6) 0.8 (0.3) 1.1 (0.3) 1.0 (0.1) 0.484 0.669
Polysomnographic sleep parameters
Time in bed; h 8.2 (1.1) – 8.3 (1.8) 7.4 (0.5) 0.154 1
Total sleep time; h 7.0 (1.5) – 7.6 (2.2) 6.8 (0.8) 0.461 1
Sleep efficiency; % 90.2 (12.8) – 93.0 (2.9) 95.1 (4.9) 0.367 0.794
Stage 1 (%TST) 13.7 (3.6) – 17.7 (7.6) 17.8 (7.0) 0.924 0.756
Stage 2 (%TST) 61.6 (30.9) – 40.1 (10.1) 40.5 (11.8) 0.303 0.595
Stage 3 (%TST) 7.0 (7.4) – 11.3 (3.3) 11.6 (2.7) 0.707 0.913
Stage 4 (%TST) 5.8 (11.3) – 7.4 (7.6) 6.2 (6.2) 0.551 0.902
REM sleep (%TST) 11.9 (15.7) – 15.6 (11.4) 20.2 (3.6) 0.276 0.815
Frequency of OSA 19.0 (135.0) – 0.5 (1.8) 2.0 (2.5) 0.575 0.491
Frequency of CSA 0.5 (5.8) – 4.0 (3.8) 0.0 (0.5) 0.267 0.108
Respiratory rate 10.0 (2.3) – 12.5 (2.5) 15 (3.5) 0.170 0.144
For questionnaires an adjusted Bonferroni signiﬁcance value of a = 0.0056 was used.
M, male; F, female; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale; ISI, Insomnia Severity Index; FSS, Fati-
gue Severity Scale; PVAQ, pain vigilance and awareness questionnaire; C-ESD, Center for Epidemiological Studies Depression
Scale; TST, total sleep time; OSA, obstructive sleep apnoeas; CSA, central sleep apnoeas.
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efﬁciency, sleep latency or awakenings in healthy indi-
viduals when taken acutely (with the effect of chronic
use largely unstudied) [9, 10]. However, we appreciate
that the small sample size and preliminary nature of this
study means that subtle effects of opioids may have been
missed.
Figure 1 Example actigraphy traces of 12 consecutive days from two controls, two patients with chronic pain who
take opioid medication and two patients with chronic pain but on treatment other than opioid medications. Black
bars indicate activity, with the same scale used for each actogram. Each actogram is 48 h double-plotted with succes-
sive days on the vertical axis. The midline of each actogram represents midnight between days 1 and 2. In this sam-
ple, actigraphy shows continuous activity during the night in patients not on opioid medication (blue bar/arrows)
while patients on opioid medication are least active during the night (red bar/arrows). Top left, 62-year-old female,
top right, 44-year-old male. Middle left, 52-year-old female morphine equivalent dose = 210 mg, middle right 41-
year-old male morphine equivalent dose = 71 mg, bottom left, 51-year-old female, bottom right 51-year-old male.
(Opioid dose expressed as morphine equivalents per day).
© 2016 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists of Great Britain and Ireland. 1301
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The effect of opioid medication on brain activity
in terms of sleep architecture is particularly interest-
ing and was only identiﬁed through polysomno-
graphic measures. Due to the resource-intense nature
of polysomnography, data collection for patients tak-
ing opioid medication was limited to patients taking
high doses. Examination of individual patient data
demonstrated markedly abnormal sleep architecture
with reduced REM, reduced stage 3/4 and longer
stage 2 sleep in two out of four patients taking high
doses of opioid medication in line with other
polysomnographic studies on opioid use (Figs. 2 and
3) [9, 10]. In healthy individuals, stage 2 sleep com-
prises around 45% of total sleep time, with REM
sleep and deep sleep (stage 3/4) each comprising
around 25%, which is similar to our controls and
patients not taking opioids (Table 1) [34]. However,
patients taking high doses of opioid medication spent
only about 12.5% of time in REM and stage 3/4
NREM sleep each, while stage 2 NREM sleep
increased to 60% of total sleep time, most likely as a
compensation for the inability to enter stage 3/4
NREM and REM sleep. Previous studies have
revealed a signiﬁcantly longer period in stage 2 sleep,
a shorter period in deep sleep and some evidence for
shorter REM sleep after acute administration of opi-
oid medication in healthy volunteers, which is sup-
ported through our ﬁndings, suggesting a continued
negative effect with chronic use [9–11]. Furthermore,
the same two patients taking high doses of opioid
medication showed a lower respiratory rate and a
considerably greater number of central and obstruc-
tive apnoeas (one night of PSG identiﬁed 57 apnoeas
in one patient and 432 in the other compared with
< 15 in all other participants). This follows previously
established evidence for respiratory depression during
sleep from opioid medication and could contribute to
additional sleep disruption in this group [15, 35, 36].
Interestingly, in this sample the majority of this
increase originated from increased obstructive sleep
apnoea (OSA, high-dose opioids, median frequency
19) as opposed to central sleep apnoea (CSA, high-
Figure 2 Top, hypnograms from two healthy controls presenting characteristic electroencephalographic correlates of
sleep and its architecture with approximate 90-min sleep cycles transitioning from wake to NREM light sleep, NREM
deep sleep and ﬁnally REM sleep.
Bottom, hypnograms from two patients taking high doses of opioids (expressed as morphine equivalents per day,
MEQ.d1). Here, abnormal sleep architecture is clearly demonstrated with a large proportion of the night awake or
in stage 2 sleep, with striking deﬁcits in REM and deep sleep. The horizontal axis begins at lights off and ends at
lights on, with the length dependent upon how long the individual tries to sleep for. The vertical axis corresponds to
vigilance state (Wake, REM: Rapid Eye Movement sleep; Stage 1: light sleep; Stage 2: durable sleep; Stage 3: transi-
tional sleep toward deep sleep; Stage 4: deep sleep).
1302 © 2016 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists of Great Britain and Ireland.
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dose opioids, median frequency 0.5). This may
reﬂect the comorbidities which are often present in
patients with lower back pain and a larger sample
size would likely elucidate this. Nevertheless, if left
untreated, patients with OSA have been shown to
develop cognitive impairment and dementia of Alz-
heimer’s type about 10 years earlier than those with-
out OSA or being treated with continuous positive
airway pressure [37].
In considering the clinical applications of these
methods, our ﬁndings suggest that, while actigraphy
facilitates collection of data over considerable stretches
of time, it should be paired with polysomnography
and subjective sleep assessments in order to give a
more comprehensive understanding. This may be par-
ticularly relevant in situations such as intensive care,
where simple environmental interventions have been
shown to improve subjective sleep quality and reduce
the odds of developing delirium [38, 39]. Here, further
in-depth investigations may elucidate the extent to
which quality of sleep (as assessed objectively by
polysomnography and actigraphy) can be improved
by such interventions. Both actigraphy and
polysomnography could be easily used in an intensive
care setting [40], with minimal disruption or discom-
fort to the patient, and the use of polysomnography in
addition to actigraphy would be especially important
given that patients in intensive care are likely to be
sedated. Furthermore, the addition of the recording of
respiratory parameters and pulse oximetry in
polysomnography could facilitate assessment of sleep
apnoea in postoperative settings, allowing enhanced
understanding of the association of obstructive sleep
apnoea with adverse peri-operative outcomes [41].
Although the long-term effect of speciﬁc sleep
stage deﬁcit is largely unknown, sleep disruption is
likely to have signiﬁcant impact on health through
suppression of its major functions, that could disrupt
memory consolidation, immune function and cognitive
performance [42]. The implications of these ﬁndings
for patient quality of life poses new considerations for
the use of opioid medication and the best strategy for
treatment of chronic pain with the minimisation of
detrimental effects on sleep. Future studies are needed
to investigate these effects of opioid medication on
brain activity with particular emphasis on high dose
Figure 3 Overnight spectral fast Fourier transform (FFT) of the central C4 electroencephalography channel.
(a) healthy control. Patterns are well matched to models of human sleep architecture. Periodic delta frequency bands
(0.5–2 Hz) representing deep sleep (stage 3 and 4) are clearly identiﬁed in pink, presenting greatest intensity from
the beginning of the night and gradually decreasing towards the end. Sigma frequency bands can also be identiﬁed
(in the range 11–14 Hz) representing sleep spindles of stage 2 sleep. Four bouts of REM sleep can be identiﬁed with
increasing duration, represented by periods of low intensity and a lack of delta frequencies.
(b) Participant on 95 mg of opioids for chronic back pain. In contrast to the healthy control, no discernible pattern
of sleep architecture is present. Instead of delta waves, this individual shows theta waves characteristic for stage 2
sleep. Both sigma and delta frequencies are nearly absent, suggesting this individual has abnormal sleep spindles and
does not enter deep sleep. Furthermore, there is an absence of REM sleep, with this individual likely alternating
between wake, stage 1 and stage 2.
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use in addition to possible differential effects between
opioid medications.
There are limitations to the conclusions that can
be drawn from this study, including the small sample
size and large range of ages included (given that age
can affect sleep and sleep structure [43]). Furthermore,
it is difﬁcult in these groups of patients to disentangle
the effects of pain and pain medication on sleep, in
addition to the potential impact of social circum-
stances. These issues may account for the lower than
expected sleep efﬁciency and increased stage 1 sleep in
the control group represented in both EEG and actig-
raphy [44]. Future studies should, therefore, use larger
sample sizes with more uniform age ranges or grouped
according to age.
Actigraphy is not designed to detect brain activity
and it cannot be used to distinguish between periods
of motionless wakefulness and a person asleep, which
may be common among this population due to a
degree of sedation caused by medication [45]. These
limitations may also apply to the use of applications
on domestic portable electronic devices (e.g. ‘apps’ on
smart phones) which monitor sleep using accelerome-
ters. Such software is becoming commonplace. The
EEG/polysomnography records cortical frequencies
but is time-intensive and, therefore, was only used in
a small subset of participants and over two nights in
this study. Despite this, polysomnography revealed
highly abnormal brain activity during sleep, and our
study suggests that it is currently the most sensitive
tool to objectively describe the sleep disruption due
to pain and medication in at-home settings. Our
study also suggests that questionnaires are vital for
evaluating the perceived sleep quality and the impact
of its disruption on quality of life with chronic pain.
Overall, this study has shown that sleep disruption
is common but heterogeneous in patients with chronic
pain being treated with opioid as well as non-opioid
medication. Proﬁling the various types of sleep disrup-
tion in patients with chronic pain required three
different methods; questionnaires; actigraphy; and
polysomnography. These data have demonstrated the
utility of subjective and objective measures in the
assessment of sleep in pain and have highlighted
the potential for opioid medications to interfere with
sleep regulation. It would, therefore, beneﬁt future
studies to take these factors into account when inter-
preting ﬁndings and a requirement for several mea-
sures of sleep quality would be optimal.
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Appendix: Questionnaire scoring
reference
Pittsburgh Sleep Quality Index (PSQI) [23]
The PSQI assesses seven components of sleep includ-
ing: subjective sleep quality; sleep latency; sleep dura-
tion; habitual sleep efﬁciency; sleep disturbances; use
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of sleeping medication; and daytime dysfunction.
Nineteen self-related questions are answered to pro-
duce a score for each component (0 = no difﬁculty,
3 = severe difﬁculty). The global PSQI score is calcu-
lated by the sum of the component scores with a range
of 0–21, with a higher score indicating a worse subjec-
tive sleep quality (for a full description of the scoring
method see Buysse et al. [23]). A cut-off score of 5
provides a sensitivity of 89.6% and a speciﬁcity of
86.5% [23] for identifying patients with poor sleep and
is widely used.
Insomnia Severity Index (ISI) [24]
The ISI consists of seven questions that require you to
rate subjective aspects of sleep. The scores are added
together to provide a composite score (range = 0–28).
Score categories are: 0–7 = no clinically signiﬁcant
insomnia; 8–14 = subthreshold insomnia; 15–
21 = Clinical insomnia (moderate severity); 22–
28 = Clinical insomnia (severe).
Pain Vigilance and Awareness Questionnaire
(PVAQ) [25]
The PVAQ contains 16 items relating to the subjects
pain-related vigilance and awareness over the last
2 weeks, each rated by the subject from 0 (never) to 5
(always) with regard to how frequently each item was
a true description of them. A composite score is then
calculated, with two items ‘reverse keyed’ [25]. A
higher score indicates increased pain vigilance and
awareness.
Centre for Epidemiological Studies Depression
Scale (C-ESD) [26]
The C-ESD is designed to measure ‘depressive symp-
tomatology in the general population’. The score con-
sists of 20 items and the subject is required to rate
how often each thought or symptom was present. The
range of scores are 0–60, with a higher score indicating
increased psychological distress, and scores > 16 sug-
gesting a clinically signiﬁcant level of psychological
distress.
The Epworth Sleepiness Scale (ESS) [27]
The ESS aims to evaluate daytime sleepiness by asking
subjects to score how likely they would be to fall
asleep in eight different, varyingly soporiﬁc situations.
Scores range between 0 and 24, with a higher score
indicating increased daytime sleepiness. A score of
over 16 indicates high levels of daytime sleepiness
compared to the general population.
Fatigue Severity Scale (FSS) [28]
The FSS assesses the impact of fatigue on daily living
with a score range of 9–63. It consists of 9 statements
for which patients select a number from 1 to 7 to indi-
cate the extent to which they agree or disagree
(1 = strongly disagree, 7 = strongly agree). A higher
score indicates a greater impact of fatigue on aspects
of daily life.
Regression analysis
Taking into account all participants on opioid medica-
tion (n = 14), linear regression revealed that a higher
amount of daily opioid dose was associated with
increased actigraphic sleep fragmentation and lower
actigraphic sleep efﬁciency (p = 0.008, p = 0.002
respectively, Fig. A1). Linear regression also revealed
that increased subjective pain rating (PVAQ) was asso-
ciated with lower actigraphic sleep fragmentation and
greater actigraphic sleep efﬁciency (p = 0.01, p = 0.017
respectively, not shown). With the exclusion of an out-
lier (3 standard deviations above mean), all linear
regression results became non-signiﬁcant (p > 0.05).
No relationship was found between opioid dosage and
pain rating, subjective sleep quality (PSQI), or any
other actigraphic measurement.
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Figure A1 Effect of daily dosage of opioid medication (morphine equivalent, MEQ) on average actigraphic sleep
efﬁciency (left) and sleep fragmentation (right), including and excluding outlier data (n = 14 and n = 13,
respectively).
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